Jefferies upgraded Zealand Pharma from Hold to Buy
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2024 | Buy | Berenberg | |
| 8/8/2023 | Equal-Weight | Morgan Stanley | |
| 11/16/2022 | Overweight → Equal-Weight | Morgan Stanley | |
| 1/11/2022 | Hold → Buy | Jefferies |
15F-12B - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
Berenberg initiated coverage of Zealand Pharma with a rating of Buy
Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight
Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,135,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.001% of the total share capital and 10.001% o
Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the ex
Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapiesUnique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammation Copenha
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog
Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth. Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indications, aiming to establish the leading amylin-based franchise.Enrolled the last participant in the large, global Phase 2 ZUPREME-1 trial with petrelintide in people with overweight or obesity, thre
Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Ke